Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives $102.00 Average PT from Analysts

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has been assigned a consensus rating of “Hold” from the twenty-three research firms that are currently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $103.5263.

A number of equities analysts have issued reports on ZBH shares. Citizens Jmp cut their target price on shares of Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating for the company in a research report on Wednesday, April 29th. Sanford C. Bernstein increased their price target on shares of Zimmer Biomet from $91.00 to $93.00 and gave the company a “market perform” rating in a research report on Thursday. Wall Street Zen downgraded Zimmer Biomet from a “buy” rating to a “hold” rating in a research report on Saturday. Stifel Nicolaus upped their target price on Zimmer Biomet from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Robert W. Baird set a $104.00 target price on Zimmer Biomet in a report on Thursday.

Insider Activity at Zimmer Biomet

In related news, insider Sang Yi sold 5,000 shares of Zimmer Biomet stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the sale, the insider owned 27,251 shares in the company, valued at approximately $2,252,022.64. This trade represents a 15.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.28% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Zimmer Biomet

Several hedge funds have recently modified their holdings of the company. DV Equities LLC purchased a new position in shares of Zimmer Biomet during the fourth quarter valued at approximately $25,000. Monetary Solutions Ltd purchased a new stake in Zimmer Biomet in the 4th quarter worth approximately $30,000. Gen Wealth Partners Inc purchased a new stake in Zimmer Biomet in the 4th quarter worth approximately $31,000. Flagship Harbor Advisors LLC acquired a new position in Zimmer Biomet in the 4th quarter valued at $32,000. Finally, Elevation Wealth Partners LLC lifted its stake in shares of Zimmer Biomet by 145.9% during the 2nd quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 229 shares during the period. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Stock Down 0.0%

ZBH opened at $96.54 on Monday. The business’s fifty day moving average is $90.17 and its two-hundred day moving average is $90.15. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69. The company has a market cap of $18.41 billion, a price-to-earnings ratio of 23.49, a PEG ratio of 3.07 and a beta of 0.45. Zimmer Biomet has a one year low of $79.12 and a one year high of $108.29.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The business had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.13 billion. During the same quarter in the previous year, the company posted $2.07 EPS. The business’s revenue was up 4.8% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Analysts anticipate that Zimmer Biomet will post 8.53 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, July 31st. Stockholders of record on Thursday, June 25th were given a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. The ex-dividend date was Thursday, June 25th. Zimmer Biomet’s dividend payout ratio is currently 23.36%.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.